Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Teen band 1Type releases single to raise awareness of type 1 diabetes
May 30, 2025Medical Communications, Medical Education 1Type, Diabetes, Rise Up, Sanofi, Stagecoach Performing Art, autoimmune type 1 diabetes
Four teenagers living with autoimmune type 1 diabetes (aT1D) have released a single aimed at raising awareness of the condition …
Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform
May 30, 2025Medical Communications, Research and Development Bill and Melinda Gates Foundation, Gene Weaver, Oncology, Pharmacy, Rare Diseases, funding, gene editing
UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …
Ochre Bio appoints Elaine Sullivan as senior independent non-executive director
May 30, 2025Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director
Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …
NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1
May 30, 2025Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder
May 29, 2025Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders
Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …
Ryvu Therapeutics appoints Justyna Żółtek to management board
May 29, 2025Medical Communications, Research and Development Oncology, Ryvu Therapeutics, chief people officer, human resources, management board, oncology
Ryvu Therapeutics has promoted Justyna Żółtek, chief people officer, to its management board. The appointment reflects the company’s focus on …
Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer
May 28, 2025Research and Development Neogap, Oncology, Swedish Medical Products Agency, colorectal cancer
Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the full dose of its investigational …
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
May 28, 2025Mergers and Acquisitions Cell and Gene Therapy (CGT), Corporate, Juno GmbH, TQ Therapeutics, juno therapeutics
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno …
UK Researcher Wins Prestigious IBSA Foundation Fellowship for Pioneering Dermatology Study
May 28, 2025Medical Communications, Research and Development Dermatology, IBSA Foundation Fellowship, Institut Biochimique SA (IBSA), Masami Ando Kuri, Milan Italy, Wellcome Sanger Institute, dermatology
Masami Ando Kuri from the Wellcome Sanger Institute named one of six global winners of the 2024 IBSA Foundation Fellowships. …
Orientation Marketing appoints Sarah Darcy as sales operations executive
May 27, 2025Marketing Services, Sales and Marketing Corporate, pharmaceutical marketing agency, sales operations executive
Orientation Marketing has announced the appointment of Sarah Darcy as sales operations executive. She joins the business-to-business (B2B) life sciences and …
The Royal Marsden launches AI radiology platform to revolutionise cancer care
May 27, 2025Analytical & Laboratory Services, Market & Product Development, Medical Education, Research and Development AI, CARPL.ai., Institute of Cancer Research, NTT DATA, National Institute for Health and Care Research, Oncology, The Royal Marsden, oncology, radiology
The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform designed to accelerate cancer detection …
MC2 Therapeutics appoints Trine Ahlgreen as new CEO
May 27, 2025Research and Development, Sales and Marketing CEO, Corporate, MC2 Therapeutics, Skin, inflammatory skin conditions
MC2 Therapeutics, a Danish pharma company focused on topical therapies for inflammatory skin conditions, has appointed Trine Ahlgreen as CEO. …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
May 23, 2025Research and Development Moderna, Oncology, START Center for Cancer Research, US
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase 1 clinical trial evaluating mRNA-4106, …
NICE recommends treatment for chronic kidney disease, IgA nephropathy
May 23, 2025Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …
CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma
May 23, 2025Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
May 23, 2025Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
May 23, 2025Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience
PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …
Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunctionÂ
May 22, 2025Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy
First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated 20 May 2025. Another Day Pharma Ltd, a company developing innovative …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
